Nisa Investment Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.28K | Buy |
109
+29
| +36% | +$653 | ﹤0.01% | 2596 |
|
|
2025
Q4 | $1.84K | Hold |
80
| – | – | ﹤0.01% | 2618 |
|
|
2025
Q3 | $2.41K | Hold |
80
| – | – | ﹤0.01% | 2583 |
|
|
2025
Q2 | $2.91K | Hold |
80
| – | – | ﹤0.01% | 2536 |
|
|
2025
Q1 | $2.9K | Hold |
80
| – | – | ﹤0.01% | 2374 |
|
|
2024
Q4 | $3.37K | Hold |
80
| – | – | ﹤0.01% | 2360 |
|
|
2024
Q3 | $4.44K | Hold |
80
| – | – | ﹤0.01% | 2240 |
|
|
2024
Q2 | $3.29K | Hold |
80
| – | – | ﹤0.01% | 2315 |
|
|
2024
Q1 | $3.73K | Hold |
80
| – | – | ﹤0.01% | 2150 |
|
|
2023
Q4 | $3.83K | Hold |
80
| – | – | ﹤0.01% | 2142 |
|
|
2023
Q3 | $2.85K | Hold |
80
| – | – | ﹤0.01% | 2324 |
|
|
2023
Q2 | $3.69K | Sell |
80
-130
| -62% | -$6.03K | ﹤0.01% | 2340 |
|
|
2023
Q1 | $8K | Hold |
210
| – | – | ﹤0.01% | 2192 |
|
|
2022
Q4 | $10K | Hold |
210
| – | – | ﹤0.01% | 2209 |
|
|
2022
Q3 | $8K | Sell |
210
-8,323
| -98% | -$428K | ﹤0.01% | 2234 |
|
|
2022
Q2 | $509K | Buy |
8,533
+8,100
| +1,871% | +$498K | ﹤0.01% | 1051 |
|
|
2022
Q1 | $31K | Sell |
433
-1,396
| -76% | -$97.1K | ﹤0.01% | 1963 |
|
|
2021
Q4 | $128K | Buy |
1,829
+127
| +7% | +$10.3K | ﹤0.01% | 1421 |
|
|
2021
Q3 | $154 | Sell |
1,702
-2,070
| -55% | -$187K | ﹤0.01% | 1515 |
|
|
2021
Q2 | $360 | Sell |
3,772
-1,450
| -28% | -$151K | ﹤0.01% | 1226 |
|
|
2021
Q1 | $595 | Hold |
5,222
| – | – | ﹤0.01% | 1123 |
|
|
2020
Q4 | $723K | Buy |
5,222
+3,337
| +177% | +$396K | ﹤0.01% | 1052 |
|
|
2020
Q3 | $155K | Buy |
1,885
+1,450
| +333% | +$120K | ﹤0.01% | 1396 |
|
|
2020
Q2 | $34K | Buy |
435
+50
| +13% | +$3.31K | ﹤0.01% | 1659 |
|
|
2020
Q1 | $17K | Buy |
385
+100
| +35% | +$5.19K | ﹤0.01% | 1741 |
|
|
2019
Q4 | $12K | Hold |
285
| – | – | ﹤0.01% | 1801 |
|
|
2019
Q3 | $12K | Buy |
285
+70
| +33% | +$3.8K | ﹤0.01% | 1745 |
|
|
2019
Q2 | $14K | Hold |
215
| – | – | ﹤0.01% | 1670 |
|
|
2019
Q1 | $15K | Hold |
215
| – | – | ﹤0.01% | 1663 |
|
|
2018
Q4 | $9K | Hold |
215
| – | – | ﹤0.01% | 1681 |
|
|
2018
Q3 | $16K | Sell |
215
-60
| -22% | -$4.88K | ﹤0.01% | 1589 |
|
|
2018
Q2 | $21K | Buy |
275
+100
| +57% | +$6.46K | ﹤0.01% | 1533 |
|
|
2018
Q1 | $9K | Buy |
+175
| New | +$8.81K | ﹤0.01% | 1688 |
|
|
2017
Q2 | – | Sell |
-270
| Closed | -$18K | – | 1860 |
|
|
2017
Q1 | $18K | Sell |
270
-230
| -46% | -$17.5K | ﹤0.01% | 1530 |
|
|
2016
Q4 | $35K | Hold |
500
| – | – | ﹤0.01% | 1488 |
|
|
2016
Q3 | $35K | Buy |
500
+200
| +67% | +$12.8K | ﹤0.01% | 1468 |
|
|
2016
Q2 | $15K | Hold |
300
| – | – | ﹤0.01% | 1712 |
|
|
2016
Q1 | $19K | Buy |
+300
| New | +$19.6K | ﹤0.01% | 1627 |
|
Other funds holding RARE
VPM
VCM
RI
SI
BG
Nisa Investment Advisors's RARE Position: Q1 2026 in Review
Nisa Investment Advisors increased its Ultragenyx Pharmaceutical (RARE) stake by 36% in Q1 2026, buying an estimated $653 and bringing the position to 109 shares worth $2.28K. The position accounts for ﹤0.01% of the portfolio, ranked #2596.
Nisa Investment Advisors first reported a position in RARE in Q1 2016 and has held it in 38 quarters since. The position peaked at $723K in Q4 2020. 296 funds tracked by Wall St. Rank hold RARE as of Q1 2026.
- Nisa Investment Advisors held 109 shares of Ultragenyx Pharmaceutical worth $2.28K as of Q1 2026.
- Nisa Investment Advisors bought 29 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $653.
- Ultragenyx Pharmaceutical made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q1 2026, its #2596 holding.
- Nisa Investment Advisors first reported a position in Ultragenyx Pharmaceutical in Q1 2016 and has held it in 38 quarters since.
- Nisa Investment Advisors's Ultragenyx Pharmaceutical position peaked at $723K in Q4 2020.
- 296 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.
Based on Nisa Investment Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.